(Tiper Stock Exchange) – Walgreens Boots Alliancea US giant active in the distribution of health and wellness products, recorded a net loss of $3.72 billion, or $4.31 per share, in the first quarter of fiscal 2023 (which ended November 30, 2022), compared with earnings of $3.58 billion, or $4.13 dollars per share, from the prior year. It weighs a burden of 6.5 billion dollars, before taxes, recognized in relation to the opioid dispute resolution and other related issues.
L’adjusted earnings per share it decreased 30.8% to $1.16, versus strong growth of 53.1% in the same quarter a year earlier, which reflected the high increase in COVID-19 vaccine volumes. The sales they decreased 1.5% to $33.4 billion (up 1.1% at constant currency). The analystsaccording to Refinitiv data, they expected earnings per share of $1.14 on revenues of $32.8 billion.
Walgreens has Earnings per share guidance maintained full-year adjusted $4.45 to $4.65 given strong core business growth that is greater than the impacts of COVID-19 for fiscal 2022 and currency-related headwinds. Also, it has increased the sales forecast for the full year $133.5 billion to $137.5 billion, reflecting the Summit Health acquisition, updated currency rates and first-quarter sales ahead of expectations.